Swiss drug maker Novartis has posted a 17 per cent rise in third-quarter net profit on strong sales of new products and the acquisition of eye care company Alcon.
The $3.15 billion (SFr3.04 billion) net profit is up from $2.68 billion in the same period of 2009.
The Basel-based company said sales had increased 13 per cent to $12.6 billion from $11.1 billion a year earlier.
Novartis said sales and earnings would have been higher if not for the weak US dollar.
The company said full-year sales excluding Alcon were expected to grow in the mid- to high-single digit range in constant currencies but noted that the boost it received from swine flu vaccines last year wouldn't occur in the fourth quarter.
In compliance with the JTI standards